Research Paper Volume 12, Issue 2 pp 1285—1303

DNAH10 mutation correlates with cisplatin sensitivity and tumor mutation burden in small-cell lung cancer

class="figure-viewer-img"

Figure 6. (A) ssGSEA enrichment scores (ES) of 55 SCLC cell lines in GDSC. (B) Potential mechanism of DNAH10 mutation to predict the resistance of cisplatin in SCLC. (C) ssGSEA ES of 12 human SCLC cell lines in three replicates. No significant difference was found between each group. ssGSEA: single sample gene-set enrichment analysis; SCLC: Small Cell Lung Cancer. ***P <0.001; **P <0.01; *P <0.05.